menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Emerging LDL Therapies

close
Emerging LDL Therapies
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    Host Dr. Alan Brown is joined by Peter P. Toth, MD, PhD, director of preventive cardiology in Sterling Rock Falls Clinic and clinical professor at the University of Illinois School of Medicine in Peoria, Illinois. Dr. Toth is the current president of the National Lipid Association.

    One of the most intensively studied drugs are statins. However, will statins continue to be the miracle drugs that health care professionals and patients rely on?  What are statins current role in therapy for dyslipidemia patients? In this discussion, Dr. Toth will address these questions. He will also review the new therapies for lowering LDL and whether LDL should continue to be the target for risk assessment and treatment.

    Brought to you by:

    NLA logo

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Host Dr. Alan Brown is joined by Peter P. Toth, MD, PhD, director of preventive cardiology in Sterling Rock Falls Clinic and clinical professor at the University of Illinois School of Medicine in Peoria, Illinois. Dr. Toth is the current president of the National Lipid Association.

    One of the most intensively studied drugs are statins. However, will statins continue to be the miracle drugs that health care professionals and patients rely on?  What are statins current role in therapy for dyslipidemia patients? In this discussion, Dr. Toth will address these questions. He will also review the new therapies for lowering LDL and whether LDL should continue to be the target for risk assessment and treatment.

    Brought to you by:

    NLA logo

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/4/20